Clinical Trial: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Brief Summary: Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Detailed Summary: Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Sponsor: Gabrail Cancer Center Research
Current Primary Outcome: Overall Response Rate [ Time Frame: Every 8 weeks from screening until documented disease progression or date of death, whichever occurs first, up to approximately 100 months. ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Gabrail Cancer Center Research
Dates:
Date Received: August 21, 2014
Date Started: August 2014
Date Completion:
Last Updated: November 3, 2016
Last Verified: November 2016